Skip to content

IGF-1 LR3: Side Effects & Safety

Part of the IGF-1 LR3 Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Overall Safety Profile

IGF-1 LR3 carries significant safety considerations due to its potency and non-specific growth-promoting effects. It is not FDA-approved for any human use and should be treated with particular caution among research peptides.

Reported Side Effects

  • Hypoglycemia: Potentially serious — IGF-1 LR3 lowers blood glucose significantly. Always have glucose available
  • Joint pain and swelling: Related to growth-promoting effects
  • Water retention: Can be significant
  • Jaw and extremity growth: With prolonged use (acromegaly-like effects)
  • Injection site reactions

Critical Safety Concerns

  • Cancer risk: IGF-1 signaling promotes cell proliferation — elevated IGF-1 is epidemiologically associated with increased cancer risk
  • Organ growth: Long-term IGF-1R activation can cause organomegaly (enlargement of internal organs)
  • No human clinical trials: Safety and efficacy in humans have not been formally evaluated

Contraindications

  • Active cancer or history of cancer
  • Diabetes or hypoglycemia-prone conditions
  • Acromegaly or gigantism
  • Pregnancy and breastfeeding

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.